Welcome to our dedicated page for Greater Cannabis Company SEC filings (Ticker: GCAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Greater Cannabis Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Greater Cannabis Company's regulatory disclosures and financial reporting.
Trafalgar Asset Management, LLC, wholly owned by Porfirio Sanchez Talavera, acquired 7,628,665 shares of Series A Preferred Stock and 1,000 shares of Series B Preferred Stock of Greater Cannabis Company, Inc., totaling 7,629,665 preferred shares. These securities carry 28,435,885 votes, representing 96.62% of the issuer’s aggregate voting power and 100% of the Series A and Series B preferred class.
The preferred shares were purchased in privately negotiated transactions under Series A and Series B Share Purchase Agreements dated June 29, 2026. As part of the change in control, Porfirio Sanchez Talavera became Chief Executive Officer, Chairman of the Board and a director, while the former CEO resigned all officer roles and will resign as director after a 10-day Rule 14f-1 period.
Trafalgar Asset Management, LLC, identified as a ten percent owner of Greater Cannabis Company, Inc., reports beneficial holdings of 7,628,665 shares of Series A Preferred Stock and 1,000 shares of Series B Preferred Stock as of June 29, 2026. The report notes that Porfirio Sanchez Talavera, as the beneficial owner of Trafalgar, may be deemed to share voting and investment power over these securities.
Greater Cannabis Company, Inc. director, CEO, Chairman and more-than-10% owner Porfirio Sanchez Talavera reported his initial beneficial holdings. He indirectly holds 1,000 shares of Series B Preferred Stock and 7,628,665 shares of Series A Preferred Stock through Trafalgar Asset Management, LLC as of June 29, 2026.
The Greater Cannabis Company, Inc. furnished a Schedule 14F-1 Information Statement reporting a change in control following a Share Purchase by Trafalgar Asset Management, LLC that gave it voting control of the company.
The filing states 7,628,665 shares of Series A Preferred and 1,000 shares of Series B Preferred were purchased, yielding approximately 96.62% of aggregate voting power as of June 29, 2026. Porfirio Sanchez Talavera was appointed Chairman and Chief Executive Officer and will remain as sole director after the 10-day Rule 14f-1 period expires.
The Greater Cannabis Company reported a change in control and leadership following privately negotiated transactions completed on June 29, 2026. Trafalgar Asset Management, LLC, owned and controlled by Porfirio Sánchez Talavera, purchased 7,628,665 shares of Series A Preferred Stock and 1,000 shares of Series B Preferred Stock, representing all outstanding shares of both classes. Based on 994,379 common shares outstanding, the preferred holdings give Trafalgar approximately 96.62% of the company’s total voting power, establishing clear voting control.
Concurrently, the company entered into Debt Cancellation and Release Agreements with certain creditors, under which specified indebtedness was compromised, settled, canceled, and extinguished. In connection with the change in control, Sánchez Talavera was appointed Chief Executive Officer, Chairman, and sole director (after a Rule 14f‑1 transition period), while long‑time executive Aitan Zacharin resigned from all officer roles and will depart the board following the required notice period.
The Greater Cannabis Company, Inc. reports unaudited results for the quarter ended March 31, 2026, with no revenue and a net loss of $33,376. Operating expenses fell to $33,376 from $43,536 a year earlier, mainly from lower stock-based and other operating costs.
Cash was only $1,439 against current liabilities of $776,464, resulting in a stockholders’ deficit of $775,025. Management explicitly concludes there is substantial doubt about the company’s ability to continue as a going concern through March 2027 without new funding.
The company continues to pursue development of a cannabinoid therapeutic licensed from Shaare Zedek Scientific Ltd., with Phase II clinical work dependent on securing specialized API and additional capital. A 1-for-1,500 reverse stock split and creation of super-voting Series B preferred shares have centralized voting control while leaving 944,935 common shares outstanding as of May 6, 2026.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.
The Greater Cannabis Company (GCAN) filed its Q3 2025 report. The company generated $0 revenue and reported a net loss of $36,099 for the quarter. For the nine months ended September 30, 2025, net loss was $669,369.
As of September 30, 2025, cash was $21,355 against $1,129,697 in current liabilities, resulting in a stockholders’ deficit of $(1,108,342). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The company completed a 1-for-1,500 reverse stock split in October 2025; shares outstanding were 900,256 as of September 30, 2025, and 944,935 as of October 22, 2025. During 2025, the FirstFire note accrued $306,323 in default penalties and interest; an amendment provides the note is deemed satisfied upon completion of the reverse split. On October 22, 2025, GCAN created Series B Convertible Preferred (1,000 shares), issuing it to the CEO in exchange for $20,000 of waived compensation; these shares carry 51.0% voting power.
The Greater Cannabis Company (GCAN) created a new Series B Convertible Preferred Stock and issued it to CEO Aitan Zacharin in exchange for waiving $20,000 of accrued compensation. The Series B carries super‑voting rights equal to 51.0% of the Company’s total voting power, giving him control of corporate decisions.
Each Series B share is convertible at the holder’s option into common stock at a rate of 100,000 common shares per preferred share, subject to customary adjustments for stock splits or combinations. The super‑voting rights terminate if any Series B is converted in part or transferred to a third party, after which the shares vote on an as‑converted basis with other classes. The Series B has no dividend rights and a liquidation preference of $0.001 per share.
The Greater Cannabis Company (GCAN) amended its report to update timing for a reverse stock split. A 1-for-1,500 reverse split is effective as of the close of business on October 16, 2025, after a one-day delay due to a FINRA Daily List omission.
The stock will trade on a post-split basis starting October 17, 2025, under ticker GCAND for twenty trading days, with new CUSIP 391657202. Issued and outstanding common shares will be reduced from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Authorized shares and the $0.001 par value are unchanged. The split also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options.